Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Emotion Regulation Program for Substance Use Disorders

NCT07698821 · tracked via the Priya Life Science South Korea tracker
Phase
Not applicable
Started
2026-09
Last updated
2026-07-13

Condition(s) studied

Substance Use Disorder (SUD)

Investigational drug(s) / intervention(s)

Emotion Regulation Program

Emotion Regulation Program: Eight 50-minute group sessions delivered twice weekly over approximately four weeks. Session 1: understanding emotions and following the body's signals. Session 2: emotion regulation strategies I (grounding oneself through the senses when shaken). Session 3: emotion regulation strategies II (practicing choice rather than being swept away by emotion). Session 4: building a personal emotion-response scenario for moments of crisis. Session 5: facing the self-critical voice. Session 6: protecting oneself with warmth in difficult moments. Session 7: noticing and savoring positive moments. Session 8: organizing a personal emotion-regulation routine to sustain going forward. Core techniques are motivational interviewing, acceptance and commitment therapy, and group therapy, incorporating emotion-regulation and self-compassion skills.

Study summary

This study examines whether a newly developed eight-session psychosocial treatment program, called the Emotion Regulation Program, can be delivered in real-world hospital settings to people receiving inpatient care for substance use disorders in Korea, and whether it shows early signs of benefit. The program combines motivational interviewing, acceptance and commitment therapy, and group activities, and is delivered twice a week over about four weeks (eight 50-minute sessions). About 20 adults will take part at two psychiatric hospitals.

Participants complete brief questionnaires and a short interview about their craving, motivation to change, difficulties in emotion regulation, self-compassion, depression, and drug use history before the program, immediately before and after each session, within one week after the program ends, and again at 1 month and 3 months after completion. After the program, some participants also join a small group discussion (focus group interview) to share their experience of the program.

Because this is a small, single-group preliminary (pilot) study without a comparison group, its primary purpose is to assess feasibility, that is, whether the program and the assessment approach work well enough, and to obtain preliminary effect and variability estimates to inform the design of a future large-scale randomized controlled trial.

Eligibility

Sex
ALL
Min age
19 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 19 to 65 years who can understand the study purpose and procedures and provide written informed consent * Currently hospitalized (inpatient) * Able to communicate and complete questionnaires in Korean * Physically able to participate in program activities * Has completed detoxification treatment * Meets indication thresholds: DAST-10 score \>= 2 and \>= 2 DSM-5 criteria Exclusion Criteria: * Cognitive impairment that precludes communication * Physical conditions that preclude program participation (e.g., musculoskeletal disorder, severe cardiopulmonary disease) * Acute psychotic symptoms or risk of self-harm or harm to others * At risk of disrupting group activities such that focus group participation is not feasible

Primary outcome measure(s)

  • Feasibility: Program Completion (Retention) Rate — From enrollment through the end of the 8-session intervention (approximately 4 weeks)
    Proportion of enrolled participants who complete all eight sessions of the Emotion Regulation Program. Feasibility is further characterized by recruitment rate, session attendance, and assessment completion rates.
  • Change in Craving (VAS-C) — Immediately before and immediately after each of the 8 sessions (over approximately 4 weeks); baseline (within 1 week before the program); within 1 week post-intervention; 1 month and 3 months after completion
    Craving measured by the Visual Analog Scale for Craving (VAS-C), ranging from 0 to 100 mm (0 = no craving, 100 = constant craving); higher scores indicate greater craving (worse outcome). Change from baseline is assessed at post-intervention and follow-up.

Trial sites (2)

FacilityCityRegionStatus
Daegu Daedong Hospital Daegu South Korea
Incheon Chamsarang Hospital Incheon South Korea

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07698821 on ClinicalTrials.gov ↗ ← All trials in South Korea